Silence Therapeutics Plc (SLNCF)
2.63
+0.27
(+11.44%)
USD |
OTCM |
May 07, 09:30
Silence Therapeutics Cash from Investing (Quarterly) : -53.92M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Adaptimmune Therapeutics Plc | 18.84M |
| Biodexa Pharmaceuticals Plc | -- |
| Oxford Biomedica Plc | -- |
| NuCana Plc | -0.0656M |
| Autolus Therapeutics Plc | 86.65M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.66M |
| Cash from Financing (Quarterly) | -0.0003M |
| Free Cash Flow | -62.89M |
| Free Cash Flow Per Share (Quarterly) | -0.1176 |
| Free Cash Flow to Equity (Quarterly) | -16.64M |
| Free Cash Flow to Firm (Quarterly) | -16.66M |
| Free Cash Flow Yield | -16.88% |